Which investors can be classified as ‘SRI’ and how much capital do they manage? Recently, the Global Sustainable Investment Alliance (GSIA) published its latest biennial market review valuing sustainable investment assets at $30.7tn globally. Different organizations (CDP, UNPRI...) quote very different large ESG market figures. Join us for our 30-min learning webinar series to help you understand why these figures look so different and help you come up with a market figure that makes sense of the actual integration of ESG by investors.
Which investors can be classified as ‘SRI’ and how much capital do they manage? Recently, the Global Sustainable Investment Alliance (GSIA) published its latest biennial market review valuing sustainable investment assets at $30.7tn globally. Different organisations (CDP, UNPRI...) quote very different large ESG market figures. Join us for our ‘30 min Lunch & Learn ESG webinar’ to help you understand why these figures look so different and help you come up with a market figure that makes sense of the actual integration of ESG by investors.
Why is now the time for small- and mid-cap biotech & pharma executives, directors, IROs and legal teams to learn more about the “Environmental, Social and Governance” (ESG) landscape, where to start and how best to communicate to investors? Given the rapid rise of interest in the topic by institutional investors and other company stakeholders, senior management teams and corporate directors increasingly need to take a proactive approach with their companies’ ESG policies and messaging. This is the case even if your shareholders and analysts have never asked you questions about ESG factors or your ESG ratings. Join ESG industry leaders for a conversation that’s specific to biotech & pharma: •
